Pharmacokinetic and pharmacodynamic interaction of siponimod (BAF312) and propranolol in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 10, 2015, Pages 855-865

  Biswal, Shibadas ^a   Polus, Florine ^b   Pal, Parsar ^a   Veldandi, Uday Kiran ^a   Marbury, Thomas C ^c   Perry, Robert ^d   Legangneux, Eric ^b  

^a NOVARTIS HEALTHCARE PVT LTD   (India)

^b NOVARTIS PHARMA AG   (Switzerland)

^c ORLANDO CLINICAL RESEARCH CENTER   (United States)

^d Elite Research Institute   (United States)

Author keywords

Drug interactions; Pharmacodynamics; Pharmacokinetics; Siponimod; blocker

Indexed keywords

PLACEBO; PROPRANOLOL; SIPONIMOD; 1-(4-(1-((E)-4-CYCLOHEXYL-3-TRIFLUOROMETHYLBENZYLOXYIMINO)-ETHYL)-2-ETHYLBENZYL)-AZETIDINE-3-CARBOXYLIC ACID; AZETIDINE DERIVATIVE; BENZYL DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRADYCARDIA; CONSTIPATION; CONTROLLED STUDY; DEPRESSED BLOOD PRESSURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; EXPLORATORY RESEARCH; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HEART RATE; HEART RHYTHM; HUMAN; HUMAN EXPERIMENT; HYPERTRANSAMINASEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN ARTERIAL PRESSURE; NORMAL HUMAN; PR INTERVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SIDE EFFECT; SINUS BRADYCARDIA; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD PRESSURE; DRUG EFFECTS; DRUG INTERACTION; MIDDLE AGED; YOUNG ADULT;

ADULT; AZETIDINES; BENZYL COMPOUNDS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; FORCED EXPIRATORY VOLUME; HEART RATE; HUMANS; MALE; MIDDLE AGED; PROPRANOLOL; YOUNG ADULT;

EID: 84946903479     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202369     Document Type: Article

References (16)

1. Gergely P, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, Pan S, Gray NS, Hinterding K, Cooke NG, Groenewegen A, Vitaliti A, Sing T, Luttringer O, Yang J, Gardin A, Wang N, Crumb WJ Jr, Saltzman M, Rosenberg M, Wallström E. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has speciesspecific effects on heart rate. Br J Pharmacol. 2012; 167: 1035-1047. CrossRef PubMed
2. Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS, Stüve O, Rieckmann P, Montalban X, Ziemssen T, Auberson LZ, Pohlmann H, Mercier F, Dahlke F, Wallström E. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013; 12: 756-767. Cross-Ref PubMed
3. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor-1. Nature. 2004; 427: 355-360. CrossRef PubMed
4. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362: 387-401. CrossRef PubMed
5. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW; FTY720 D2201 Study Group. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006; 355: 1124-1140. CrossRef PubMed
6. Koch M, Kingwell E, Rieckmann P, Tremlett H; UBC MS Clinic Neurologists. The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010; 81: 1039-1043. CrossRef PubMed
7. Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler. 2008; 14: 1091-1098. CrossRef PubMed
8. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C; Task Force On Beta-Blockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004; 25: 1341-1362. CrossRef PubMed
9. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. General considerations for lung function testing. Eur Respir J. 2005; 26: 153-161. CrossRef PubMed
10. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010; 9: 883-897. Cross-Ref PubMed
11. Mazurais D, Robert P, Gout B, Berrebi-Bertrand I, Laville MP, Calmels T. Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem. 2002; 50: 661-670. CrossRef PubMed
12. Gergely P, Wallström E, Nuesslein-Hildesheim B, et al. Phase I study with the selective S1P1/S1P5 receptor modulator BAF312 indicates that S1P1 rather than S1P3 mediates transient heart rate reduction in humans. Mult Scler. 2009; 15: S125-S126.
13. Legangneux E, Gardin A, Johns D. Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects. Br J Clin Pharmacol. 2013; 75: 831-841. PubMed
14. Lalonde RL, Pieper JA, Straka RJ, Bottorff MB, Mirvis DM. Propranolol pharmacokinetics and pharmacodynamics after single doses and at steady-state. Eur J Clin Pharmacol. 1987; 33: 315-318. CrossRef PubMed
15. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007; 115: 84-105. CrossRef PubMed
16. Pavia D, Bateman JR, Lennard-Jones AM, Agnew JE, Clarke SW. Effect of selective and non-selective beta blockade on pulmonary function and tracheobronchial mucociliary clearance in healthy subjects. Thorax. 1986; 41: 301-305. CrossRef PubMed